Drug Trial Radar · NCT05789342
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Feb 15, 2023
Primary completion
Sep 11, 2023
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a four-part, single-center, Open label phase I clinical study to characterize the DDIs potential of GP681 With Rosuvastatin, Digoxin, Itraconazole or Oseltamivir in Chinese healthy volunteers. This study also aims to evaluate the safety and tolerability of GP681 in the presence of Rosuvastatin, Digoxin, Itraconazole, or Oseltamivir.
Conditions
- Healthy Volunteers
Interventions
GP681Drug
GP681, tablet, oral
RosuvastatinDrug
Rosuvastatin, tablet, oral
DigoxinDrug
Digoxin, tablet, oral
ItraconazoleDrug
Itraconazole, capsule, oral
OseltamivirDrug
Oseltamivir, capsule, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part one: Peak plasma concentration (Cmax) of RosuvastatinTime frame: Day 1 to Day 4, and Day 8 to Day 11
- Part one: Area under the plasma concentration versus time curve (AUC) of RosuvastatinTime frame: Day 1 to Day 4, and Day 8 to Day 11
- Part two: Peak plasma concentration (Cmax) of DigoxinTime frame: Day 1 to Day8, and Day 15 to Day 22
- Part two: Area under the plasma concentration versus time curve (AUC) of DigoxinTime frame: Day 1 to Day 8, and Day 15 to Day 22
- Part three: Peak plasma concentration (Cmax) of GP681Time frame: Day 1 to Day12, and Day26 to Day 37
- Part three: Area under the plasma concentration versus time curve (AUC) of GP681Time frame: Day 1 to Day 12, and Day26 to Day 37
- Part Four: Peak plasma concentration (Cmax) of GP681Time frame: 264 hours after GP681 administration
- Part Four: Area under the plasma concentration versus time curve (AUC) of GP681Time frame: 264 hours after GP681 administration
- Part Four: Peak plasma concentration (Cmax) of OseltamivirTime frame: 12 hours after Oseltamivir administration
- Part Four: Area under the plasma concentration versus time curve (AUC) of OseltamivirTime frame: 12 hours after Oseltamivir administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.